Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01786239 · ClinicalTrials.gov registry record · NA
Omega-3 Dietary Supplements in Schizophrenia
A NA study of Schizophrenia and Bipolar Disorder, sponsored by Delbert Robinson.
- Completed
- Registry status
- NA
- Development phase
- 50
- Enrollment target
- 1
- Study location
NCT01786239 is a NA study of Schizophrenia and Bipolar Disorder that has completed, run by Delbert Robinson. The registered enrollment target is 50 participants, below the 219-participant average among 315 other Schizophrenia trials with a reported enrollment target (77% lower). The trial reports 1 study location across 1 state.
The verdict
NCT01786239, a NA study of Schizophrenia and Bipolar Disorder, has completed, sponsored by Delbert Robinson.
- COMPLETED
- Registry status
- NA
- Development phase
- 50 participants
- Enrollment target
- 1
- Study location
Study Summary
This 16-week placebo-control study looks to investigate whether patients with schizophrenia for two years or less may benefit from omega-3 supplements.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Risperidone
- DRUG Omega-3 capsules
Study Locations (1)
New York
- The Zucker Hillside Hospital - Glen Oaks
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2013-05 |
| Est. Completion | 2015-09 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01786239
The ClinicalTrials.gov registry entry for NCT01786239 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 219-participant average among 315 other Schizophrenia trials with a reported enrollment target (77% lower). The listed sponsor is Delbert Robinson, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 5 conditions, with Schizophrenia appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT01786239 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT01786239 about?
NCT01786239 is a clinical study titled "Omega-3 Dietary Supplements in Schizophrenia". This 16-week placebo-control study looks to investigate whether patients with schizophrenia for two years or less may benefit from omega-3 supplements.
What is the current status of trial NCT01786239?
This trial is currently completed. It is a NA study. The enrollment target is 50 participants. The study started on 2013-05. Estimated completion is 2015-09.
What conditions does trial NCT01786239 study?
This clinical trial studies the following conditions: Schizophrenia, Bipolar Disorder, Schizoaffective Disorder, Schizophreniform Disorder, Psychosis NOS.
What interventions are being tested in trial NCT01786239?
The interventions under investigation include: Placebo (DRUG), Risperidone (DRUG), Omega-3 capsules (DRUG).
Who is sponsoring clinical trial NCT01786239?
This trial is sponsored by Delbert Robinson, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01786239 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Schizophrenia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Taking Action for College Students
RECRUITING · NA
-
Enhancing Prefrontal Oscillations and Working Memory in Early-course Schizophrenia
RECRUITING · NA
-
Getting Out of the House: Using Behavioral Activation to Increase Community Participation
RECRUITING · NA
-
Enhancing Brain Connectivity in Schizophrenia Through Neuromodulation (Study 1)
RECRUITING · NA
-
Cerebellar Modulation of Cognition in Psychosis
RECRUITING · NA
-
TMS for Inhibition Enhancement in Schizophrenia
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.